Bay Area biotech unicorn suffers 5th worst Wall Street debut of year

Cromwell Schubarth
Bay Area biotech unicorn suffers 5th worst Wall Street debut of year

The San Francisco company's market cap dropped by about $700 million in its first day of trading.